From: Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
Characteristics (total patients = 89) |  |
---|---|
Female, n (%) | 78 (87.6) |
Age, mean ± SD | 46.8 ± 11.2 |
Years of migraine history, mean ± SD | 28.2 ± 13.3 |
Baseline MMDs, mean ± SD | 19.8 ± 8.4 |
Baseline analgesic days, mean ± SD | 13.5 ± 10.6 |
Baseline triptan days, mean ± SD | 8.7 ± 10.4 |
Chronic migraine, n (%) | 84 (94.4) |
Aura, n (%) | 27 (30.3) |
Allodynia, n (%) | 33 (37.1) |
Medication overuse, n (%) | 64 (71.9) |
Previous preventive treatment failures, n (%) | |
 2 | 28 (31.5) |
 3 | 24 (27.0) |
 4 | 26 (29.2) |
 > 4 | 11 (12.4) |
Botulinum toxin failure, n (%) | 44 (49.4) |
Concurrent oral preventive treatments at baseline, n (%) | 37 (41.6) |